NAAG Endorses the FIGHT Act

This legislation is crucial to federal and state efforts to curb the opioid epidemic nationally and within each individual state. It is for these reasons that we commend Senators Portman and Manchin for their leadership in bringing forward this important legislation, and we urge you to take up and pass S. 2701 before the DEA’s temporary order expires.

Read More →

NAAG to Congress: Reauthorize Violence Against Women Act

As the legislative history of VAWA has shown, members from both sides of the aisle have come together to strengthen existing protections and fill gaps in the law. We, therefore, urge you to work together as leaders of your respective caucuses and committees to act before VAWA expires and pass a VAWA reauthorization bill that continues to ensure our nation’s most vulnerable victims are not left behind.

Read More →

NAAG Supports Equal Coronavirus Relief Funding for the District of Columbia

We believe that the District should receive $1.25 billion for purposes of the relief package. The District has nearly 200 confirmed coronavirus cases, which outpaces nearly two dozen states and territories. Indeed, as a densely populated urban center, the District is uniquely vulnerable to the spread of the virus and is already experiencing significant economic loss due to the ongoing public health emergency.

Read More →

NAAG Urges FDA to Include AGs in Oversight of Cannabis-Derived Products

As the primary enforcers of our respective states’ consumer protection laws, we offer a unique perspective as to the new legalized market of certain cannabis and cannabis-derived compounds, including CBD products. We write to express our hope that the FDA continues to explore manufacturing, testing, and marketing best practices so that consumers are not at risk of misleading advertising or harm to their health from dangerous additives or undisclosed risks of use. Although products containing cannabis or cannabis-derived compounds may well offer real benefits to consumers, it is important that consumers have reliable risk and benefit information to make informed choices about initiating and continuing the use of these products. A crucial element of FDA regulation and oversight should be an on-going assessment of the potential risks or benefits of these products, particularly for specific populations such as pregnant women, adolescents and children, and the elderly. How these products interact with other dietary or pharmaceutical products should be included in this assessment. It is also important that companies not mislead consumers. Scientific and medical data from the FDA would assist in meaningful enforcement of advertising laws and regulations by the states.

Read More →

AGs Send Policy Guidelines to Streaming Industry to Combat Youth Tobacco Use

Given the recent significant rise in tobacco use by young people, particularly the use of e-cigarettes, preventing initiation and use of tobacco products is of critical importance to us and the public health community, and we sincerely hope it will be addressed by the streaming industry.

Read More →